BR0309339A - Vìrus vaccinia modificado ankara para a vacinação de neonatos - Google Patents

Vìrus vaccinia modificado ankara para a vacinação de neonatos

Info

Publication number
BR0309339A
BR0309339A BR0309339-5A BR0309339A BR0309339A BR 0309339 A BR0309339 A BR 0309339A BR 0309339 A BR0309339 A BR 0309339A BR 0309339 A BR0309339 A BR 0309339A
Authority
BR
Brazil
Prior art keywords
vaccination
virus
modified vaccinia
antigens
relates
Prior art date
Application number
BR0309339-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Chaplin
Mark Suter
Mathias Ackermann
Marco Franchini
Sabine Vollstedt
Hans Peter Hefti
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0309339(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of BR0309339A publication Critical patent/BR0309339A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0309339-5A 2002-04-19 2003-04-16 Vìrus vaccinia modificado ankara para a vacinação de neonatos BR0309339A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200590 2002-04-19
PCT/EP2003/003994 WO2003088994A2 (en) 2002-04-19 2003-04-16 Modified vaccinia virus ankara for the vaccination of neonates

Publications (1)

Publication Number Publication Date
BR0309339A true BR0309339A (pt) 2005-03-08

Family

ID=29225556

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309339-5A BR0309339A (pt) 2002-04-19 2003-04-16 Vìrus vaccinia modificado ankara para a vacinação de neonatos

Country Status (23)

Country Link
US (3) US7897156B2 (enExample)
EP (4) EP2204179A3 (enExample)
JP (4) JP4801880B2 (enExample)
KR (2) KR101028937B1 (enExample)
CN (1) CN100540051C (enExample)
AT (1) ATE366586T2 (enExample)
AU (1) AU2003239805B2 (enExample)
BR (1) BR0309339A (enExample)
CA (1) CA2478009C (enExample)
CY (1) CY1106848T1 (enExample)
DE (1) DE60314823T3 (enExample)
DK (1) DK1420822T4 (enExample)
EA (1) EA011233B1 (enExample)
ES (1) ES2288609T5 (enExample)
IL (1) IL163701A0 (enExample)
MX (1) MXPA04010353A (enExample)
NO (1) NO336348B1 (enExample)
NZ (2) NZ536592A (enExample)
PL (1) PL220781B1 (enExample)
PT (1) PT1420822E (enExample)
SG (1) SG173216A1 (enExample)
UA (1) UA85371C2 (enExample)
WO (1) WO2003088994A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20122302U1 (de) * 2000-11-23 2005-02-24 Bavarian Nordic A/S Variante des Modifizierten Vaccinia-Ankara-Virus
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
JP4801880B2 (ja) * 2002-04-19 2011-10-26 バヴァリアン・ノルディック・アクティーゼルスカブ 新生仔予防接種用変異ワクシニアウイルスアンカラ
AU2003294248A1 (en) * 2002-11-07 2004-06-03 Aventis Pasteur, Inc. Smallpox vaccine regimen
NO347468B1 (no) * 2005-02-23 2023-11-13 Bavarian Nordic As Et modifisert Vacciniavirus Ankara (MVA) for anvendelse ved immunisering.
EP1835031A1 (en) * 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
EP2635687B1 (en) 2010-11-05 2016-12-21 Bavarian Nordic A/S Modulation of immune responses by the poxviral k4 protein
CN108126204A (zh) 2011-03-11 2018-06-08 特斯通有限责任合伙公司 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法
US10973892B2 (en) * 2012-09-04 2021-04-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
EP2968524A1 (en) * 2013-03-15 2016-01-20 Bavarian Nordic A/S Single high dose of mva induces a protective immune response in neonates and infants
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
UA113442C2 (xx) 2015-01-27 2017-01-25 Ентеросорбент
WO2016144564A2 (en) * 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
IL261321B2 (en) * 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
SG11201807051VA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
CN116162654A (zh) 2018-09-15 2023-05-26 纪念斯隆凯特琳癌症中心 用于癌症免疫疗法的重组痘病毒
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2023118508A1 (en) * 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914408A (en) * 1973-10-12 1975-10-21 Univ Nebraska Vaccine for neonatal calf diarrhea
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPS6035647A (ja) † 1983-08-09 1985-02-23 Nippon Denso Co Ltd アンチスキツド制御装置
US6248333B1 (en) * 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5403582A (en) * 1993-01-21 1995-04-04 Nippon Zeon Co., Ltd. Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US6190655B1 (en) * 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0758397B1 (en) * 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
UA68327C2 (en) † 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
NZ331369A (en) 1996-02-21 2001-04-27 Franco Lori Use of a genetic construct that directs virus expression in a lymphoid organ or a transduced cell thereof for genetic immunization
MY150893A (en) † 1996-09-24 2014-03-14 Bavarian Nordic As Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO1998017283A1 (en) * 1996-10-25 1998-04-30 The Wistar Institute Of Anatomy & Biology Method of vaccinating infants against infections
US6204250B1 (en) * 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
GB0023203D0 (en) * 2000-09-21 2000-11-01 Isis Innovation Vaccination method
GB9711957D0 (en) † 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
AU3910097A (en) 1997-08-05 1999-03-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Live recombinant vaccine comprising inefficiently or non-replicating vir us
CN1298851C (zh) 1998-11-18 2007-02-07 牛津生物医学（英国）有限公司 多肽
GB2370571B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd A modified 5t4 antigen
NZ521270A (en) * 2000-03-14 2003-06-30 Bavarian Nordic As Altered strain of the Modified Vaccinia virus Ankara (MVA) for growth in a continuous vero cell line
CN1443076A (zh) 2000-05-24 2003-09-17 梅瑞尔公司 猪生殖和呼吸综合症病毒(prrsv)重组禽痘病毒疫苗
AU2001268452B2 (en) * 2000-06-15 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses
AR029954A1 (es) * 2000-07-11 2003-07-23 Bayer Ag Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
DE20122302U1 (de) * 2000-11-23 2005-02-24 Bavarian Nordic A/S Variante des Modifizierten Vaccinia-Ankara-Virus
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
AU2002356690B2 (en) * 2001-12-04 2008-07-24 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
JP4801880B2 (ja) 2002-04-19 2011-10-26 バヴァリアン・ノルディック・アクティーゼルスカブ 新生仔予防接種用変異ワクシニアウイルスアンカラ
EP2253709B1 (en) * 2002-05-16 2018-04-11 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
RU2337835C2 (ru) * 2003-09-10 2008-11-10 Ра Брэндз, Л.Л.С. Процесс выполнения вдавленного узора на композитной вентилируемой планке
ES2476990T3 (es) * 2003-11-12 2014-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sistema para tratar y prevenir cáncer de mama
US7618980B2 (en) * 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8613936B2 (en) * 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements

Also Published As

Publication number Publication date
US8163293B2 (en) 2012-04-24
US20090104224A1 (en) 2009-04-23
DE60314823D1 (de) 2007-08-23
ES2288609T5 (es) 2017-11-13
DE60314823T3 (de) 2017-11-16
EP1420822A2 (en) 2004-05-26
AU2003239805B2 (en) 2009-09-10
US20120183574A1 (en) 2012-07-19
EP2204180A3 (en) 2010-12-22
EP1420822B1 (en) 2007-07-11
DK1420822T3 (da) 2007-10-08
JP5690214B2 (ja) 2015-03-25
JP2010120955A (ja) 2010-06-03
US20110135683A1 (en) 2011-06-09
SG173216A1 (en) 2011-08-29
EA011233B1 (ru) 2009-02-27
KR101028937B1 (ko) 2011-04-12
US7897156B2 (en) 2011-03-01
UA85371C2 (ru) 2009-01-26
AU2003239805A1 (en) 2003-11-03
NZ547776A (en) 2009-08-28
NO336348B1 (no) 2015-08-03
PL371594A1 (en) 2005-06-27
ATE366586T2 (de) 2007-08-15
MXPA04010353A (es) 2005-03-07
CA2478009C (en) 2019-03-26
EP2204180A2 (en) 2010-07-07
EP1839672A3 (en) 2007-11-21
HK1078777A1 (zh) 2006-03-24
EP2204179A2 (en) 2010-07-07
EA200401405A1 (ru) 2005-04-28
IL163701A0 (en) 2005-12-18
CA2478009A1 (en) 2003-10-30
EP1420822B2 (en) 2017-07-05
EP1839672A2 (en) 2007-10-03
NO20044941L (no) 2004-11-12
JP2015061876A (ja) 2015-04-02
EP2204179A3 (en) 2010-12-22
JP2011157400A (ja) 2011-08-18
WO2003088994A3 (en) 2004-02-19
ES2288609T3 (es) 2008-01-16
CY1106848T1 (el) 2012-05-23
PT1420822E (pt) 2007-09-04
PL220781B1 (pl) 2016-01-29
DK1420822T4 (en) 2017-10-09
NZ536592A (en) 2007-01-26
DE60314823T2 (de) 2008-03-13
KR20040111467A (ko) 2004-12-31
CN100540051C (zh) 2009-09-16
CN1646158A (zh) 2005-07-27
JP2005523318A (ja) 2005-08-04
KR20110017904A (ko) 2011-02-22
JP4801880B2 (ja) 2011-10-26
WO2003088994A2 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
BR0309339A (pt) Vìrus vaccinia modificado ankara para a vacinação de neonatos
Tsukiyama-Kohara et al. Tupaia belangeri as an experimental animal model for viral infection
DK0610250T3 (da) Vaccine med porcint reproduktivt respiratorisk syndrom og diagnose heraf
BR9911163A (pt) Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
EP4185598A4 (en) TYPE 1 IFN ASSAYS AND METHODS FOR DIAGNOSIS OF SUSCEPTIBILITY TO AND TREATMENT OF VIRURAL DISEASES AND VIRUS VACCINES WITH COVID-19
Fenner Vaccinia virus as a vaccine, and poxvirus pathogenesis
Zhang et al. Type III interferon gene expression in response to influenza virus infection in chicken and duck embryonic fibroblasts
KR102723171B1 (ko) 신규한 코로나 바이러스의 에피토프 및 이의 용도
CN109414488A (zh) 马流感病毒减毒活疫苗
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
Egberink et al. Isolation and identification of a poxvirus from a domestic cat and a human contact case
JPWO2002062381A1 (ja) バキュロウイルスベクターワクチン
Goswami et al. Are We Sure that Drug Can Cure or the Vaccine is Genuine to Restrain Mpox to be Benign: A Brief Review
Wills et al. Immunogenicity of wild-type and vaccine strains of Japanese encephalitis virus and the effect of haplotype restriction on murine immune responses
Chakraborty et al. Effect of pure atropine and atropine sulfate on Japanese encephalitis virus infection in chick chorio allantoic membrane
ATE86308T1 (de) Menschlicher b-lymphotroper virus (hblv), isolierung und erzeugnisse.
Zhang et al. Nutritional Considerations in COVID-19 Pandemic
Webber The practice of clinical virology: Virus taxonomy
RU2175555C2 (ru) Способ получения вируса-индуктора интерферона
Yamamura et al. Effect of diethylpyrocarbonate on the antiviral and interferon-inducing activities of viral and nonviral agents
HK40095531A (en) Type 1 ifn assays and methods of diagnosis for susceptibility to and treatment of viral disease and viral vaccines, including covid-19
Kannan et al. Evolving trends in molecular virulence, pathogenesis, symptomatology and epidemiology of recent Middle East respiratory syndrome coronavirus (MERS-CoV)
Rytel Possible Role of Interferon in Control of Respiratory Infections in Recruits

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]